PHARMA CBD SPAC LENUS
The LENUS SPAC provides pre-IPO investment opportunities for investors who are keen to participate in the development of the pharmaceutical cannabis industry.
THE STRATEGY OF LENUS BIOSCIENCE SPAC
LENUS BIOSCIENCE SPAC targets to acquire companies in the area of medical cannabis (R&D, pharmaceutical production, distribution of pharmaceutical products that create synergies and bring new technologies and a new approach in their business combination together.
BIOTECH, NANOTECH AND MEDICAL CBD/THC
We believe, that each of these three areas holds significant growth potential and that our team will indeed succeed building a company that combines those areas.
Experts from the financial business and the biotech industry will together evaluate companies to acquire at least 200% to 400% of the IPO proceeds in enterprise value.
GLOBAL CONSENSUS ON GROWTH POTENTIAL
Expecting medical cannabis having a share of one-third of the gross market of legal cannabis and legal cannabis hitting $61 billion, this would result in a $20 billion market for medical cannabis worldwide.
New Frontier Data bases these projections on the markets that have already passed such legal initiatives and don’t include additional states that could come on board in 2019, e.g. Texas and Wisconsin neither, that regarding legalization in the European Union or elsewhere in the world.
With a budget of $1.3 trillion in health care spending, European government-subsidized health care systems will bring the medical cannabis market to dominate Europe and become the largest medical marijuana market in the world.
Germany is poised to be the leader of the European cannabis market, and Italy is expected to be second with $1.2 billion in sales by 2027; Cyprus may produce €235m worth of medicinal cannabis every year.
LATEST UPDATE (29 April 2020)
We are working to submit the final S1 version to SEC in May 2020.
USD 4,5 sponsor capital have been secured and the SPAC may float its IPO with IPO proceeds target of USD 90 million.
However, there is still room for additional sponsor capital of up to USD 3 million for a short period. Increasing the sponsor capital to USD 7,5 million will increase the IPO proceeds target to USD 150 million, leading to larger post-IPO acquisitions.
Sponsors will receive founder shares of the SPAC, which will be exchanged with common shares on the day of IPO. Additionally, sponsors receive one full warrant per each USD invested.
This is a last chance for investors to participate in this very interesting SPAC.